Business Context and Reporting Period
Aptevo Therapeutics Inc. (APVO) filed a Current Report on Form 8-K dated May 23, 2025. The filing reports the completion of a reverse stock split of the Company's common stock, effective at 5:01 p.m. Eastern Time on May 23, 2025.
Key Financial Metrics
This filing is a corporate action report and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes
- Reverse Stock Split: The Board of Directors approved a 1-for-20 reverse stock split. Every 20 shares of issued and outstanding common stock were automatically combined into one share.
- Trading Adjustments: The Company's common stock began trading on a split-adjusted basis on The Nasdaq Capital Market on May 27, 2025.
- Security Identifiers: The new CUSIP number for the common stock is 03835L 504.
- Equity Instruments: Proportionate adjustments were made to the exercise prices and share counts of outstanding stock options, restricted stock units, and warrants. No fractional shares were issued; cash payments were made in lieu of fractional shares.
Guidance, Outlook, and Risks
The filing includes forward-looking statements regarding the reverse stock split. Management highlights several risks that could cause actual results to differ from expectations, including:
- The Company's ability to continue as a going concern.
- Deterioration in business prospects.
- Adverse events or unanticipated problems in clinical development and trials.
- Changes in regulatory, social, macroeconomic, and political conditions.
The Company disclaims any obligation to update these forward-looking statements.
Investor Verification Checklist
- Verify the new CUSIP number (03835L 504) for trading purposes.
- Confirm the adjusted share count and exercise prices for any held options, warrants, or RSUs.
- Review the Company's most recent 10-K or 10-Q filings for financial health and going concern status, as this 8-K does not provide financial data.
- Monitor the stock price performance on The Nasdaq Capital Market starting May 27, 2025.